A spatiotemporal atlas of mouse liver homeostasis and regeneration

share:

Brief intro:

  • Author: Jiangshan Xu, Shijie Hao, Quan Shi, Keke Huang, Juan An, Mengnan Cheng, Xiao Zhang, Haitao Nan, Xinyi Shentu, Xiaoyu Wei, Xin Huang, Yumo Song, Zhifeng Wang, Shiping Liu, Tao Yang, Wensi Du, Tanveer Ahmed, Zhen Dai, Baoming Qin, Liangxue Lai, Junling Chen, Yongyin Li, Michael Ott, Tobias Cantz, Karsten Kristiansen, Berthold G?ttgens, Lijian Hui, Longqi Liu, Yiwei Lai & Miguel A. Esteban
  • Journal: Nature Genetics
  • Publication Date: 2024 Apr 16

Products/Services used in the paper

Request Quote

Abstract

The mechanism by which mammalian liver cell responses are coordinated during tissue homeostasis and perturbation is poorly understood, representing a major obstacle in our understanding of many diseases. This knowledge gap is caused by the difficulty involved with studying multiple cell types in different states and locations, particularly when these are transient. We have combined Stereo-seq (spatiotemporal enhanced resolution omics-sequencing) with single-cell transcriptomic profiling of 473,290 cells to generate a high-definition spatiotemporal atlas of mouse liver homeostasis and regeneration at the whole-lobe scale. Our integrative study dissects in detail the molecular gradients controlling liver cell function, systematically defining how gene networks are dynamically modulated through intercellular communication to promote regeneration. Among other important regulators, we identified the transcriptional cofactor TBL1XR1 as a rheostat linking inflammation to Wnt/β-catenin signaling for facilitating hepatocyte proliferation. Our data and analytical pipelines lay the foundation for future high-definition tissue-scale atlases of organ physiology and malfunction.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download